PriceTargets.com logo

Mesoblast - MESO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.67
  • Forecasted Upside: 117.62%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.28 As of 04/26/2024 04:36 PM ET
▲ +0.13 (2.11%)

This chart shows the closing price for MESO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mesoblast Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MESO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MESO

Analyst Price Target is $13.67
▲ +117.62% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mesoblast in the last 3 months. The average price target is $13.67, with a high forecast of $34.00 and a low forecast of $3.00. The average price target represents a 117.62% upside from the last price of $6.28.

This chart shows the closing price for MESO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Mesoblast. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
9/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$34.00Low
8/31/2023Jefferies Financial GroupUpgradeHold ➝ BuyLow
8/31/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$46.00 ➝ $34.00Low
8/7/2023Maxim GroupDowngradeBuy ➝ HoldLow
8/4/2023Chardan CapitalLower TargetSell ➝ Sell$4.00 ➝ $3.00Low
8/4/2023Piper SandlerDowngradeOverweight ➝ Neutral$14.00 ➝ $4.00Low
8/4/2023William BlairDowngradeOutperform ➝ Market PerformLow
5/30/2023Chardan CapitalLower Target$5.00 ➝ $4.00Low
3/9/2023William BlairInitiated CoverageOutperform$16.00Low
3/1/2023Chardan CapitalReiterated RatingSell$5.00Low
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$46.00Low
12/6/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
9/6/2022Piper SandlerInitiated CoverageOverweight$14.00Low
6/3/2022Chardan CapitalLower TargetSell$13.00 ➝ $5.00Low
9/3/2021Cantor FitzgeraldReiterated RatingOverweightN/A
8/31/2021HC WainwrightReiterated RatingBuy$32.00High
8/31/2021Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
8/31/2021Chardan CapitalLower TargetSell$15.00 ➝ $13.00High
4/13/2021Maxim GroupUpgradeHold ➝ BuyN/A
4/7/2021Maxim GroupUpgradeHold ➝ Buy$36.00High
1/19/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
12/22/2020Maxim GroupDowngradeBuy ➝ HoldLow
12/15/2020HC WainwrightReiterated RatingBuy$40.00High
12/4/2020Chardan CapitalDowngradeNeutral ➝ Sell$11.00 ➝ $15.00High
11/20/2020HC WainwrightBoost TargetBuy$38.00 ➝ $40.00High
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$24.00Low
10/5/2020Maxim GroupLower Target$44.00 ➝ $36.00Low
10/2/2020HC WainwrightLower TargetBuy$42.00 ➝ $38.00High
8/14/2020Maxim GroupBoost TargetBuy$32.00 ➝ $44.00High
5/29/2020Maxim GroupInitiated CoverageBuy$32.00High
5/28/2020LADENBURG THALM/SH SHBoost TargetBuy$26.00 ➝ $30.50Low
5/28/2020HC WainwrightReiterated RatingPositive ➝ Buy$28.00 ➝ $42.00Low
4/27/2020HC WainwrightReiterated RatingBuy$28.00High
4/9/2020HC WainwrightReiterated RatingBuyN/A
2/28/2020Maxim GroupReiterated RatingBuy$32.00Medium
2/6/2020HC WainwrightReiterated RatingBuy$28.00Low
12/19/2019Dawson JamesInitiated CoverageBuy$28.00Low
11/27/2019Maxim GroupReiterated RatingBuy$32.00Low
11/26/2019HC WainwrightReiterated RatingBuy$16.00High
10/22/2019Cantor FitzgeraldReiterated RatingOverweight$46.00Low
9/12/2019Maxim GroupReiterated RatingBuy$32.00N/A
9/10/2019Cantor FitzgeraldSet TargetBuy$46.00Medium
9/10/2019OppenheimerSet TargetBuy$20.00N/A
8/30/2019HC WainwrightSet TargetBuy$14.00Low
8/30/2019Chardan CapitalSet TargetHold$12.00Low
6/12/2019Maxim GroupReiterated RatingBuy$32.00Low
6/5/2019HC WainwrightInitiated CoverageBuy$14.00Low
5/31/2019Chardan CapitalSet TargetHold$12.00Medium
5/30/2019Maxim GroupInitiated CoverageBuy$32.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 9 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mesoblast logo
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $6.28
Low: $6.04
High: $6.36

50 Day Range

MA: $3.71
Low: $1.97
High: $6.59

52 Week Range

Now: $6.28
Low: $1.61
High: $10.24

Volume

276,951 shs

Average Volume

1,778,281 shs

Market Capitalization

$716.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Mesoblast?

The following Wall Street analysts have issued research reports on Mesoblast in the last twelve months: Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group Inc., Maxim Group, Piper Sandler, StockNews.com, and William Blair.
View the latest analyst ratings for MESO.

What is the current price target for Mesoblast?

3 Wall Street analysts have set twelve-month price targets for Mesoblast in the last year. Their average twelve-month price target is $13.67, suggesting a possible upside of 122.2%. Cantor Fitzgerald has the highest price target set, predicting MESO will reach $34.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $3.00 for Mesoblast in the next year.
View the latest price targets for MESO.

What is the current consensus analyst rating for Mesoblast?

Mesoblast currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MESO, but not buy more shares or sell existing shares.
View the latest ratings for MESO.

What other companies compete with Mesoblast?

Other companies that are similar to Mesoblast include Cullinan Oncology, Cabaletta Bio, HilleVax, CARGO Therapeutics and Relay Therapeutics. Learn More about companies similar to Mesoblast.

How do I contact Mesoblast's investor relations team?

Mesoblast's physical mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company's listed phone number is (139) 639-6036 and its investor relations email address is [email protected]. The official website for Mesoblast is www.mesoblast.com. Learn More about contacing Mesoblast investor relations.